On October 14, 2026, the DEA published two new notices of intent in the Federal Register that restructure its kratom-related scheduling actions. The first replaces the pending 7-hydroxymitragynine ...

In November 2025, Congress passed a new federal definition of “hemp” that restricts the commercial hemp industry nationwide. Under Section 781 of the Continuing Appropriations, Agriculture, ...

At its October 8 meeting, the Massachusetts Cannabis Control Commission (CCC) voted to continue to authorize administrative ...

The Drug Enforcement Administration’s (DEA) Chief Administrative Law Judge Derek C. Julius stayed the marijuana rescheduling proceeding (DEA Docket No. 1362; Hearing Docket No. 26-96) on September 29.

The New York Office of Cannabis Management (OCM) will open applications for adult-use nursery licenses on November 5, 2026, the first nursery license application window since the regulated adult-use ...

On September 11, 2026, the Florida Department of Health announced its Final Order, officially closing the April 2023 Medical Marijuana Treatment Center (MMTC) application process and granting 22 new ...

Kratom, derived from the leaves of a Southeast Asian tree, is sold across the United States in supplements and beverages, and federal regulators have spent years evaluating whether specific ...

Medical marijuana is finally “rescheduled,” but if you own, lease, or broker cannabis real estate, the headlines are oversimplifying what it means for your lease. They make it sound like an automatic ...

North Carolina has spent the better part of a decade as one of the most permissive hemp markets in the country. Walk into a shop in Raleigh, Asheville, or Wilmington today, and you’ll still find ...

On August 6, 2026, New York’s Cannabis Control Board (the Board) issued its first declaratory ruling interpreting what “sole control” requires of a Conditional Adult-Use Retail Dispensary (CAURD) ...

Alcohol and Tobacco Tax and Trade Bureau (TTB) licensing governs which federal permits, registrations, formulas and label approvals an alcohol beverage business needs before it can produce, import or ...

A botanically derived, non-opioid pain treatment made from cannabis is moving through regulatory review in Europe and the United States, adding to growing evidence that supported the FDA’s 2024 ...